small nucleolar RNA, H/ACA box 79Genealiases: ACA65 · SNORA79A
Q-omics provides the consensus-scored SNORA79 profile across patient tissues and cancer cell-line models. SNORA79 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNORA79 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, SNORA79 RNA expression shows 5,891 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, THCA, and STAD as cancer lineages where SNORA79 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA79 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA79 survival associations across molecular data types. SNORA79 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA79 RNA expression–survival associations across cancer types. High SNORA79 expression shows unfavorable associations in ACC, DLBC, COAD, THCA, LIHC and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SNORA79 RNA expression.
This table summarizes SNORA79 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA79. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA79 shows lower tumor expression in THCA and higher tumor expression in UCEC, HNSC and LUAD. The THCA box plot shows higher SNORA79 RNA expression in normal versus tumor tissue (log2 FC = −0.206, t-test p = .004).
This table shows molecular features associated with SNORA79 in patient tissues and cancer cell lines. In patient samples, SNORA79 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
